 SAN DIEGO, April 27, 2021 GLOBE NEWSWIRE -- Daré Bioscience, Inc. NASDAQ:DARE, a leader in womens health innovation, today announced that data from the Companys postcoital test PCT clinical study of its novel investigational hormone-free monthly intravaginal contraceptive, Ovaprene, will be presented at the 2021 American College of Obstetricians and Gynecologists ACOG Annual Clinical and Scientific Meeting. The meeting will be conducted virtually from April 30 - May 2, 2021. 